Creating a blood test for herpes simplex viruses 1 and 2.
Official title: SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
Funded at Immport Therapeutics, INC. · NIH-11203298 · Data updated 2026-11-12
This study is working on a new blood test to help doctors quickly find out if someone has a herpes infection, which could make it easier to manage and treat the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immport Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | September 10, 2024 |
| Project end | September 9, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 75N93024C00044-0-9999-1 |
| Project ID | NIH-11203298 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of or currently experiencing symptoms related to herpes simplex virus infections.
✕Less likely to help
Patients who have already been diagnosed and are receiving effective treatment for herpes simplex infections may not benefit directly from this research.
What this research studies
This research focuses on developing a serological test to detect infections caused by Herpes Simplex Virus types 1 and 2. The approach involves creating a diagnostic tool that can identify these viruses through a simple blood test, which could help in early detection and management of the infections. By improving diagnostic capabilities, the research aims to provide healthcare providers with better tools to diagnose and treat patients effectively.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and accessible testing for herpes simplex infections, improving patient care.
How similar studies have gone: Previous research has shown promise in developing serological tests for viral infections, indicating potential success for this approach.
Where this research is happening
-
Immport Therapeutics, INC.
Irvine, United States Active
Researchers
- Principal investigator: Camerini, David — Immport Therapeutics, INC.
- Study coordinator: Camerini, David
Related research
Other NIH-funded projects on the same topics.
-
Sensitive test to gauge whole cell pertussis vaccine potency
A new blood test is being developed to better measure how strong a whole-cell pertussis vaccine is, which could help ensure vaccines released to patients are safe and effective.
-
Cryptosporidium vaccine: making better immunity for infants
A new vaccine approach aims to boost antibodies and gut immunity in young children to prevent Cryptosporidium infection and related health problems in LMICs.
-
Broadly protective vaccine candidates for Group A Streptococcus (GAS) to prevent common and serious GAS infections
Researchers are developing a GAS vaccine aimed at protecting people of all ages from common and severe GAS infections and reducing immune-related complications.
-
Protective human antibodies to prevent Cryptosporidium illness in infants and young children
A patient-friendly approach to help vulnerable kids get passive immunity through powerful antibodies to cryptosporidiosis.
-
Antibody protection against tummy viruses in Bangladeshi mothers and babies
Researchers will look for antibodies in mothers, breast milk, and infants in Bangladesh that protect babies from viral diarrhea.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.